ORNIDAZOLE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C7H10ClN3O3
Molecular Weight	219.626
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC=C(N1CC(O)CCl)[N+]([O-])=O

InChI

InChIKey=IPWKIXLWTCNBKN-UHFFFAOYSA-N

InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3

HIDE SMILES / InChI

Molecular Formula	C7H10ClN3O3
Molecular Weight	219.626
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3663242 | https://www.ncbi.nlm.nih.gov/pubmed/12044544 | https://www.medicineindia.org/pharmacology-for-generic/474/ornidazole | http://www.druginfosys.com/drug.aspx?drugcode=2018&type=1 | http://www.uf.ua/int/post.php?id=50 | https://www.ncbi.nlm.nih.gov/pubmed/15825069

Ornidazole is nitroimidazole derivative. It is an antiprotozoal drug that has proven to be effective against Trichomonas vaginalis, Entoamoeba histolytica, Giardia lamblia and Helicobacter pylori. The reduction of the nitro group and the generation of short-lived reactive intermediates are the basis of its parasiticidal activity. Ornidazole is a DNA-tropic drug with selective activity against microorganisms with enzyme systems capable of reducing the nitrogroup and catalyze the interaction between ferrodoxin proteins and nitrocompounds. After the drug penetrates the microbial cell, the mechanism of its action is based reducing the nitrogroup under the influence of the microorganism’s nitroreductases and the activity of the reduced nitroimidazole. The reduction products create compounds with DNA causing it to degrade, and disrupt the DNA replication and transcription processes. Furthermore, the drug’s metabolism products have cytotoxic properties and disrupt cellular respiration processes. It is indicated for the treatment of anaerobic systemic infections caused by ornidazole-sensitive microflora, prevention of infections caused by anaerobic bacteria, during operative treatment (especially middle and straight intestine surgeries), gynecological surgeries, severe intestinal ameobiasis, all extra-intestinal ameobiasis forms, giardiasis. Ornidazole was shown to be effective for the prevention of recurrence of Crohn's disease after ileocolonic resection.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 282 Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3663242 \| https://www.ncbi.nlm.nih.gov/pubmed/12044544	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Anaerobic bacterial infections 8 Sources: http://www.uf.ua/int/post.php?id=50 http://www.druginfosys.com/drug.aspx?drugcode=2018&type=1 https://www.medicineindia.org/pharmacology-for-generic/474/ornidazole http://www.drugsupdate.com/generic/view/368/Ornidazole-	Curative	Approved 8583	Ornidazole Approved Use Indications for Ornidazole 1.Amoebiasis 2.Giardiasis 3.Trichomonas vaginitis 4.Anaerobic bacterial infections 5.Bacterial vaginosis
Crohn's disease 64 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15825069	Preventing	Phase II 1147	Unknown Approved Use Unknown
Giardiasis 13 Sources: http://www.uf.ua/int/post.php?id=50 http://www.druginfosys.com/drug.aspx?drugcode=2018&type=1 https://www.medicineindia.org/pharmacology-for-generic/474/ornidazole http://www.drugsupdate.com/generic/view/368/Ornidazole-	Curative	Approved 8583	Ornidazole Approved Use Indications for Ornidazole 1.Amoebiasis 2.Giardiasis 3.Trichomonas vaginitis 4.Anaerobic bacterial infections 5.Bacterial vaginosis

C_max

Value	Dose	Co-administered	Analyte	Population
16185 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25384588/	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:		ORNIDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
332948 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25384588/	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:		ORNIDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
14.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25384588/	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:		ORNIDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13 h OTHER GOV'T https://www.medsafe.govt.nz/profs/datasheet/a/arrowornidazoletab.pdf	unknown		ORNIDAZOLE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
87% OTHER GOV'T https://www.medsafe.govt.nz/profs/datasheet/a/arrowornidazoletab.pdf	unknown		ORNIDAZOLE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
500 mg 2 times / day multiple, oral Highest studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16770616/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16770616/	Disc. AE: Vertigo... AEs leading to discontinuation/dose reduction: Vertigo (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/16770616/

AEs

AE	Significance	Dose	Population
Vertigo	1 pt Disc. AE	500 mg 2 times / day multiple, oral Highest studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16770616/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16770616/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP3 246 BSEP 550 BCRP 910 MRP2 499 CYP19A1 429 MRP4 290 CYP1A2 2153 CYP2C19 2057 P-gp 1741	UGT1A1 479 UGT1A8 323 UGT1A9 423 UGT1A10 331 CYP3A 220 UGT2B15 236 UGT2B17 237 UGT1A6 343 UGT1A4 399 P-gp 2052 UGT2B4 278 UGT1A3 470 UGT2B7 456 UGT1A7 249

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28061#section=Biological-Test-Results Page: 15.0	inconclusive [IC50 38.9018 uM]
BSEP 554	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE0NDk2NzYifX0=	no [IC50 >133 uM]
MRP2 625	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1NzQ4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE0NDk2NzYifX0=	no [IC50 >133 uM]
MRP3 326	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1OTE4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE0NDk2NzYifX0=	no [IC50 >133 uM]
MRP4 345	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE0NDk2NzYifX0=	no [IC50 >133 uM]
BCRP 985	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28061#section=Biological-Test-Results Page: 60.0	no
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28061#section=Biological-Test-Results Page: 240.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28061#section=Biological-Test-Results Page: 298.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28061#section=Biological-Test-Results Page: 298.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28061#section=Biological-Test-Results Page: 292.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28061#section=Biological-Test-Results Page: 269.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28061#section=Biological-Test-Results Page: 288.0	no
MRP1 232	activator 342 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28061#section=Biological-Test-Results Page: 45.0	no
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28061#section=Biological-Test-Results Page: 62.0	no

Drug as victim

Target	Modality	Activity	Clinical evidence
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23571427/	major [Km 1200 uM]
UGT1A9 423	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23571427/	major [Km 12400 uM]
UGT1A8 323	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23571427/	minor
UGT1A10 331	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23571427/	no
UGT1A6 343	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23571427/	no
UGT2B15 236	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23571427/	no
UGT2B17 237	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23571427/	no
UGT1A1 479	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23571427/	weak
UGT1A3 470	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23571427/	weak
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23571427/	weak
UGT1A7 249	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23571427/	weak
UGT2B4 278	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23571427/	weak
P-gp 2052	substrate 4014 Sources: https://www.actapharmsci.com/uploads/pdf/pdf_141.pdf	yes
CYP3A 220	substrate 4014 Sources: https://www.actapharmsci.com/uploads/pdf/pdf_141.pdf	yes	weak (co-administration study) Comment: Silymarin increased ornidazole AUCinf by 30.25% and Cmax by 16.25%. Sources: https://www.actapharmsci.com/uploads/pdf/pdf_141.pdf

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28061#section=Biological-Test-Results Page: 299.0

PubMed

Title	Date	PubMed
Laparoscopic restorative total proctocolectomy with ileal pouch anal anastomosis for familial adenomatous polyposis.	2008-09-04	18765048
Development and validation of column high-performance liquid chromatographic and derivative spectrophotometric methods for determination of levofloxacin and ornidazole in combined dosage forms.	2008-08-30	18727534
Correlation between CD4 counts of HIV patients and enteric protozoan in different seasons - an experience of a tertiary care hospital in Varanasi (India).	2008-08-20	18713475
A comparison of metronidazole and single-dose ornidazole for the treatment of dientamoebiasis.	2008-06	18397330
Characterization and ornidazole release in vitro of a novel composite film prepared with chitosan/poly(vinyl alcohol)/alginate.	2008-05	17806112
Laparoscopic management of symptomatic Meckel's diverticula: a simple tangential stapler excision.	2008-04-12	18402742
Effects of some antibiotics on human erythrocyte glutathione reductase: an in vitro study.	2008-02	18341267
SodiumPhosphate (NaP) versus polyethylene glycol-electrolyte lavage solution (PEG-ELS) tolerability: a prospective randomized study in patients with gynecological malignancy.	2008	18459553
Severe hepatitis with prolonged cholestasis and bile duct injury due the long-term use of ornidazole.	2007-12-14	18074740
Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study.	2007-12	18237031
Simultaneous determination of seven nitroimidazole residues in meat by using HPLC-UV detection with solid-phase extraction.	2007-10-01	17719280
[Investigation of Aspergillus galactomannan levels in antimicrobial agents].	2007-10	18173075
Validated HPTLC method for simultaneous estimation of levofloxacin hemihydrate and ornidazole in pharmaceutical dosage form.	2007-09	18019564
Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.	2007-09	17334763
An improved HPLC method for determination of nifuratel in human plasma and its application to pharmacokinetics studies.	2007-08-19	17702193
Nonoperative treatment of acute appendicitis in children.	2007-08	17706511
Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase.	2007-08	17676992
Study on poly(vinyl alcohol)/carboxymethyl-chitosan blend film as local drug delivery system.	2007-06	17268861
Some drugs inhibit in vitro hydratase and esterase activities of human carbonic anhydrase-I and II.	2007-03-02	18048959
W/O/W multiple emulsions containing nitroimidazole derivates for vaginal delivery.	2007-03	17454033
[Post-traumatic necrotizing fasciitis].	2007-01	17095183
Maintenance of surgically induced remission of Crohn's disease.	2007	18239404
Effect of rifampicin pretreatment on the transport across rat intestine and oral pharmacokinetics of ornidazole in healthy human volunteers.	2007	17708065
The application of resonance light scattering technique for the determination of tinidazole in drugs.	2007	17671612
[Urokinase-type plasminogen activator improves the reproductive function of male rats].	2006-11	17146917
Stereoselective pharmacokinetics of ornidazole after intravenous administration of individual enantiomers and the racemate.	2006-11	16906493
Antimicrobial drug ornidazole inhibits hamster sperm capacitation, in vitro.	2006-11	16777375
[Postoperative recurrence in Crohn's disease. Risk factors and methods of prevention].	2006-10	17193847
Dissolution and vaginal absorption characteristics of metronidazole and ornidazole.	2006-10	17069425
Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.	2006-10	16985094
Review article: recurrence of Crohn's disease after surgery - the need for treatment of new lesions.	2006-10	16961741
Review article: can post-operative recurrence in Crohn's disease be prevented?	2006-10	16961740
Treatment of rheumatoid arthritis with ornidazole: a randomized, double-blind, placebo-controlled study.	2006-10	16770616
Kikuchi Fujimoto disease secondary to Entamoeba histolytica: case report.	2006-10	16442163
Chiral separation of rac-Ornidazole and detection of the impurity of (R)-Ornidazole in (S)-Ornidazole injection and raw material.	2006-08	16642497
Postoperative maintenance therapy for inflammatory bowel disease.	2006-07	16760753
In vivo and real time determination of ornidazole and tinidazole and pharmacokinetic study by capillary electrophoresis with microdialysis.	2006-06-16	16698213
Amoebic dysentery.	2006-06	16973041
Determination of gatifloxacin and ornidazole in tablet dosage forms by high-performance thin-layer chromatography.	2006-05	16770055
Treatment of rheumatoid arthritis with ornidazole. A randomized, double-blind, placebo-controlled study.	2006-05	16436488
Febrile neutropenia as the presenting sign of appendicitis in an adolescent with acute myelogenous leukemia.	2006-03-07	16517543
Decreased susceptibility to nitroimidazoles among Bacteroides species in Brazil.	2006-01	16391998
Antispermatogenic activity of the benzothiazoline ligand and corresponding organoantimony(V) derivative in male albino rats.	2006	17496999
Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A.	2006	17152348
Bioadhesive controlled release systems of ornidazole for vaginal delivery.	2006	17101518
[Clinical and microbiological efficacy of metronidazole and ornidazole in the treatment of urogenital trichomoniasis in men].	2006	16734361
Amoebic dysentery.	2005-12	16620441
Fixed drug eruption caused by ornidazole.	2005-11	16283910
A multicenter point-prevalence study: antimicrobial prescription frequencies in hospitalized patients in Turkey.	2005-10-03	16202139
[Double blind randomized multicentre study of a seven-day eradication regime of Helicobacter pylori by omeprazole, clarithromycin and ornidazole vs. omeprazole, clarithromycin and metronidazole].	2002-10	16737149

Patents

Sample Use Guides

In Vivo Use Guide

Typical Dosage for Ornidazole Amoebiasis: Adults: 1gm daily in 2 divided doses for 7 to 10 days Children: 10 to 25mg/kg once daily for 3days Amoebic dysentery: Adults: 1.5gm once daily for 3 days Children: 40mg/kg once daily for 3 days Trichomoniasis Adults: 1.5gm single daily dose or 0.5gm 12hourly for 5 days, Male partner should be concurrently treated. Children: 25mg/kg as a single dose Giardiasis: Adults: 1 to 1.5gm once daily for 2days Children: 40mg/kg for 2days Bacterial vaginosis: 1.5gm once or 500mg once daily for 5 to7 days

Route of Administration: Other

In Vitro Use Guide

Ornidazole minimum lethal concentration against Dientamoeba fragilis: 8 to 16 μg/ml

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:57:07 GMT 2025` Edited by `admin` on `Mon Mar 31 17:57:07 GMT 2025`
Record UNII	62XCK0G93T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NSC-95075

Preferred Name

English

ORNIDAZOLE

Official Name

English

ORNIDAZOLE [MI]

Common Name

English

RO-7-0207

Code

English

RO 7-0207

Code

English

ORNIDAZOLE [USAN]

Common Name

English

ornidazole [INN]

Common Name

English

RO-70207

Code

English

ORNIDAZOLE [MART.]

Common Name

English

1H-IMIDAZOLE-1-ETHANOL, .ALPHA.-(CHLOROMETHYL)-2-METHYL-5-NITRO-

Systematic Name

English

?-(Chloromethyl)-2-methyl-5-nitroimidazole-1-ethanol

Systematic Name

English

Ornidazole [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QP51AA03